期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

纤溶酶原系统与盆腔炎

Interaction between Pelvic Inflammatory Disease and Plasminogen System
下载PDF
导出
摘要 盆腔炎可引发多种疾病,如不孕、慢性盆腔疼痛及异位妊娠等,对现代女性的生活质量有很大影响。纤溶酶原系统包括纤溶酶原激活物因子和纤溶酶原激活物抑制因子,这两种因子都与盆腔炎关系密切,本文就纤溶酶原系统与盆腔炎的关系进行扼要的综述。 Pelvic inflammatory disease is currently the most common disease in females and is associated with serious long term consequences, such as chronic pelvic pain, ectopic pregnancy and infertility. So it has a great influence on women＇s life. Plasminogen activators and plasminogen activator inhibitors are included in the plasminogen system, which are closely related with pelvic inflammatory disease. This review focuses on the interaction between pelvic inflammatory disease and plasminogen system.
作者 胡晓彦
机构地区 浙江省江山市双塔社区卫生服务中心
出处 《药学与临床研究》 2013年第2期163-165,共3页 Pharmaceutical and Clinical Research
关键词 盆腔炎 纤溶酶系统 综述 Pelvic inflammatory disease Plasminogen system Review
分类号 Q55 [生物学—生物化学] R711.33 [医药卫生—妇产科学]
  • 相关文献

参考文献24

  • 1Lijnen HR, Collen D. Mechanism of physiological fibri- nolysis[J]. Bcdllieres Clin Haematol, 1995, 8(2): 277-90.
  • 2Mondino A, Blasi F. uPA and uPAR in fibrinolysis, immunity and patholory [J]. Trends Immunol, 2004, 25 (8): 450-5.
  • 3WiersingaWJ, Kager LM, Hovius JW, et al. Urokinase receptor is necessary for bacterial defense against pneumonia-derived septic melioidosis by facilitating phagocytosis[J]. J Immunol, 2010, 184(6): 5079-86.
  • 4Renckens R, Roelofs JJ, Florquin S, et al. Urokinase- type plasminogen activator receptor plays a role in neu- trophil migration during lipopolysaccharide-induced peri- toneal inflammation but not during Escherichia coli-in- duced peritonitis[J]. J Infect Dis, 2006, 193(4): 522-30.
  • 5Edelstam G, Lecander I, Larsson B, Astedt B. Fibrinol- ysis in the peritoneal fluid during adhesions, en- dometriosis and ongoing pelvic inflammatory disease [J] Inflammation, 1998, 22(4): 341-51.
  • 6Gershtein ES, Kushlinskii NE. Urokinase and tissueplasminogen aetivators and their inhibitor PAI-1 in hu- man tumors[J]. Bull Exp Bio Med, 2001, 131(1): 67-72.
  • 7Moraitis S, Taitzoglou IA, Tsantarliotou MP, Boscos CM, Kaldrimidou E, Saratsis P. Involvement of the plasminogen activation system in cow endometritis [J]. Theriogenology, 2004, 61(2-3): 337-49.
  • 8Yeh YH, Wang PH, Lin LY, et al. Significantly in- creased concentration of soluble urokinase-type plas- minogen activator receptor in the blood of patients with pelvic inflammatory disease [J]. Clin Chim Acta, 2012, 415C: 138-44.
  • 9Hsiao PC, Wang PH, Tee YT, et al. Significantly in- creased concentration in plasma monocyte chemotactic protein 1 of patients with pelvic inflammatory disease [J]. Reprod Sci, 2010, 17: 549-55.
  • 10Lee SA, Wang PH, Chiou HL, Chou MC, Tsai HT, Yang SF. Markedly increased plasma myeloperoxidase protein in patients with pelvic inflammatory disease who have A allele myeloperoxidase gene polymorphism [J]. Fertil Steril, 2010, 93(4): 1260-6.

二级参考文献30

  • 1Graham RA, Serf MW, Aplin JD, etal. An endometrial factor in unexplained infertility. BMJ, 1990,300:1428-1431.
  • 2Richards EM, Makri SM, Preston FE. The suecessful use of protein C concentrate during pregnancy in a patient with type 1 protein C deficiency, previous trombosis and recurrent fetal loss. Br J Haematol , 1997, 98 : 660- 661.
  • 3Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood, 2000, 95: 1517-1532.
  • 4Rechtman MP, Zhang J, Salamonsen LA. Effect of inhibition of matrix metalloproteinases on endometrial decidualization and implantation in mated rats. J Reprod Fertil, 1999, 11:169-177.
  • 5lwai N, Shimoikc H, Nakamura Y, et al. The 4G/5G polymorphisro of the plasminogen activator inhibitor gene is associated with the time course of progression to a cute coronary, syndromes. Atherosclerosis, 1998, 136 : 109-114.
  • 6Glueck CJ, Phillips H, Cameron D, et al. The 4G/5G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: an independent risk factor for serious pregnancy complications. Metabolism, 2000, 49: 845-852.
  • 7Ogasawara M, Aoki K, Okada S, et al. Embryonic karyotype of abortuses in relation to the number of previous miscarriages. Fertil Steril, 2000, 73: 300-304.
  • 8Sibai BM, Mirro R, Chesney CN, et al. Low-dose aspilin in pregnancy. Obstet Gynecol, 1998,74:551.
  • 9Bruse C, Guan Y, Carlberg M, et al. Basal release of urokinase plasminogen activator, plasminogen activator inhibitor-1, and soluble plasminogen activator receptor from separated and cultured endometriotic and endometrial stromal and epithelial cells [ J ]. Fertil Steril, 2005,83 : 1155-1160.
  • 10Diamanti-Kandarakis E, Palioniko G, Alexandraki K, et al. The prevalence of 4G/SG polymorphism of plasminogen activator inhibitor-1 ( PAI-1 ) gene in polycystic ovarian syndrome and its association with plasma PAl-1 levels [ J ]. Eur J Endocrinol,2004,150:793-798.

共引文献5

药学与临床研究
2013年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部